# March 4, 2016 Financial Technology Partners

FT Partners Research - Transaction Profile





\$800,000,000

Courtesy of:



The Only Investment Bank
Focused Exclusively on Financial Technology
www.ftpartners.com

Steve McLaughlin
Managing Partner
Tel: 415.992.8880

steve.mclaughlin@ftpartners.com

Financial Technology Partners LP

555 Mission St., 23<sup>rd</sup> Floor San Francisco, CA 94105 Tel: 415.512.8700





Brightree is an industry leader in post-acute technology and solutions with an unmatched footprint

The acquisition will allow ResMed to drive further enhancements and innovations for a broader range of healthcare providers

The acquisition adds efficiencies and allows expansion to other market segments

## **ResMed Acquires Brightree for \$800 million**

## **Transaction Summary**

#### **Transaction Summary**

- On February 22, 2016, ResMed announced an agreement to acquire privately-held Brightree for \$800 million
  - Deal will be financed with debt and cash on hand
  - Closing expected by the end of fiscal Q4 2016 (June), subject to customary closing conditions
- This transaction benefits ResMed in the following ways:
  - Significantly strengthens connected healthcare solutions, adding to software revenue growth
  - Immediately accretive to gross margins and non-GAAP diluted earnings per share after close
  - Estimated \$300 mm tax benefit, expected to positively impact cash flows over 15 years
- Upon completion, Brightree will continue to operate as a separate entity managed independently

#### **Transaction Commentary**

brightree. "The Brightree team is very excited to join forces with ResMed to help post-acute care providers navigate the inherent complexities of the healthcare system and ensure that patients get the care they need."

**Dave Cormack CEO** 

"This acquisition furthers ResMed's position as the leading tech-driven medical device company and gives our customers new tools to help them increase operational efficiency and improve cash-flow while delivering best-in-class patient care. ResMed is already the recognized global leader in remote patient monitoring and connected healthcare solutions. This acquisition will enable us to add to our portfolio of digital solutions to drive operational excellence and improve outcomes for patients, providers and payers."

**Mick Farrel CEO** 

<b>Brightree Multip</b>	les & Statistics
-------------------------	------------------

Englis of manipies a Granding					
2015 CY Revenue	\$113 mm	EV / 2015 CY Rev.	7.1 x		
2015 CY Recurring Revenue	80%+	EV / 2015 CY EBITDA With estimated \$300 mm tax benefit	13.5 x		
2015 CY EBITDA	~43 mm	EV / 2015 CY EBITDA Without estimated \$300 mm tax benefit	18.6 x		





## **ResMed Acquires Brightree for \$800 million**

## **Brightree Overview**

#### **Company Stats**

2,500 total customers

\$14 billion value of claims filed

48 million total patients

8 million new patients added in 2015 YTD August

17 Industry **Recognition Awards** 

## FINANCIAL TECHNOLOGY **PARTNERS**

#### **Company Overview**



**Dave Cormack** CEO



**Paul Parrish CFO** 

Founded: 2002 Employees: 450 **HQ:** Atlanta, GA

- Brightree provides cloud-based clinical, revenue cycles, and business management software solutions for the post-acute care industry serving companies ranging from HME/DME to rehab home care segments.
- First dedicated post-acute care vendor to become a member of the CommonWell Alliance, a not-for-profit organization focused on advancing HCIT interoperability

#### **Product Overview**

#### **HME/DME Software**

- Efficiently manage workflow and streamlines pay process
- Web-based software reduces IT overhead costs
- System ensures compliance
- Improved purchasing accuracy and efficiency

#### **Hospice Software**

- home hospice care providers
- standard care planning
- Results in predictable patient

#### **Home Health Software**

- Cloud-based back-office system with a native iPad point-of-care application
- Decrease AQ time, speed billing, reduce costs and protect reimbursements

#### **Pharmacy Software**

- Singular platform for all home infusion, HME pharmacy and supply needs
- Construct business rules at the payer and product level to reduce denials and establish standard procedures

#### **Transaction History**

Date	Size (\$ mm)	Туре	Target / Investor
			Acquired:
01/13/14	NA	M&A	<b>STRATEGIC</b> AR
			Acquired:
11/22/13	NA	M&A	MedAct We've Got it Covered
			Acquired:
01/04/13	NA	M&A	#Care Anyware
			Acquired:
02/02/11	NA	M&A	PACWARE SOFTWARE
			Acquired:
08/05/10	NA	M&A	COMPUTER APPLICATIONS UNLIMITED
			Acquired:

12/22/08 NA M&A





Financed by:

Financing 07/15/08 NA











## **ResMed Acquires Brightree for \$800 million**

#### **ResMed Overview**

#### **Company Overview**



Michael Farrell CEO



Robert Douglas
President & COO



Brett Sandercock
CFO



**David Pendarvis**Chief Administrative
Officer, Global General
Counsel


ResMed is a global leader in developing, manufacturing, distributing, and marketing medical equipment for respiratory disorders with a strong focus on sleep-disordered breathing


HQ: San Diego, CA Founded: 1989 Employees: 4,340

Ticker: NYSE: RMD Market Cap.: ~\$8 bn

#### Revenue Breakdown







#### **Product Overview**

**Masks:** Combine lightweight comfort with a minimal design to provide superior fit and seal, ensuring effective therapy



**Devices:** Designed to give you a more natural breathing experience, offering quiet therapy and user-friendly technology to enhance comfort and ease of use



**Dental:** Lightweight, low profile design of oral appliances, custom made to put personal comfort first



**Humidifiers:** Designed to complement sleep apnea products, ensuring relief from dryness and nasal congestion



**Accessories:** Complementary and replaceable products to ensure continuation of therapy

#### **Key Financial Metrics (LTM as of 12/31/15)**

Total Revenue (mil.)	\$1,741.7
Growth Over Prior Year	+7.8%
Gross Profit (mil.)	\$1,016.0
Margin %	58.3%
EBITDA (mil.)	\$493.9
Margin %	24.0%
Net Income (mil.)	\$349.4
Margin %	20.1%
Diluted EPS Excl. Extra Items	\$2.46




## FT Partners is the Leader in Financial Technology Investment Banking

FT Partners has advised on some of the most prominent transactions in the Healthcare and Insurance IT sectors









- Offers integrated SaaS technologies and services for healthcare premium billing, payment and workflow management
- Serves tens of thousands of US employers and millions of American families through private exchanges, state-based marketplaces and over 100 health plan and TPA customers
- Offers end-to-end Revenue Cycle Management, Quality and Care Coordination and Physician Advisory Services
- Differentiated solutions span the entire healthcare revenue cycle
- Infused management model integrates people, processes and technology

- Performs outsourced healthcare Payment Integrity and Recovery Services
- Medicare Recovery
   Audit Contractor
   ("RAC") for Region A
   (Northeast)
- Recovered ~\$482 mm in improper Medicare payments in 2012

- Largest wholesale broker in the U.S. by premiums placed (1)
- Group Benefits division develops, distributes and administers benefits products through 7 individual operating companies
- Division services approximately 843,000 member lives among 10,000 employer groups

- Provides technologyenabled content and communication, agency automation and business intelligence tools
- Serves the employee benefits and P&C insurance distribution industry
- Software and products are used by more than 2,600 agencies





## FT Partners Advises Benaissance on its \$80 mm Sale to WEX

#### **Transaction Overview and Rationale**

#### Overview of Transaction

- On October 15, 2015, Benaissance, LLC ("Benaissance" or the "Company") announced it has entered into a definitive agreement to be acquired by WEX for \$80mm
- Headquartered in Omaha, NE, Benaissance is a leading provider of integrated Software-as-a-Service (SaaS) technologies and services for healthcare premium billing, payment and workflow management
  - Existing investors include Omaha-based, McCarthy Capital
- WEX is a leading, multi-channel provider of corporate payment solutions representing more than 9 million vehicles and serving a wide variety of business sectors
- The transaction is expected to close in the fourth quarter of 2015 and is subject to applicable regulatory approvals and other customary closing conditions

#### Significance of Transaction

- Represents a highly-attractive outcome for both Benaissance and WEX
- Combined resources and expertise of Benaissance and WEX position the Company extraordinarily well to further its leadership in the marketplace
- Enables WEX to provide an expanded and differentiated payments solution in order to grow its addressable market opportunity and wallet share in the healthcare market
- Benaissance will be integrated with WEX's existing Evolution1
  platform creating an opportunity for potential synergies as the
  businesses already share a number of mutual partners and
  customers

#### FT Partners' Role

- FT Partners served as exclusive strategic and financial advisor to Benaissance and its Board of Directors
- Transaction highlights FT Partners' continued success advising leading companies and generating highly successful outcomes in the Healthcare / Benefits IT and Services space

## Financial Technology Partners LP FTP Securities LLC

is pleased to announce its exclusive role as sole strategic and financial advisor to



in its sale to



for a total consideration of

\$80,000,000



The Only Investment Bank
Focused Exclusively on Financial Technology



## Selected FT Partners' Research (click to view)



New Mountain Capital Acquires Equian for \$225 million



PointClickCare Files for its IPO



Benaissance's Sale to WEX for \$80 million



Inovalon Acquires Avalere for \$140 million



Pamplona Acquires MedAssets for \$2.7 billion



PlanSource Raises \$70 million



FT Partners regularly publishes research highlighting the most important transactions, trends and insights impacting the global Financial Technology landscape. Our unique insight into FinTech is a direct result of executing hundreds of transactions in the sector combined with over 13 years of exclusive focus on Financial Technology. Please visit our subscription form to subscribe to our exclusive monthly newsletter and receive our research reports.



## Award-Winning Investment Banking Franchise Focused on Superior Client Results

FT Partners has been recognized as Investment Banking Firm of the Year and regularly achieves Merger and Financing Deal of the Year recognition



■ Financing Deal of the Year - Equity

■ Financing Deal of the Year - Debt





Middle Market

**Financing Awards** 

2006

## **The FT Partners Senior Banking Team**

Name / Position	Prior Background	Experience / Education	Years of Experience
Steve McLaughlin Founder, CEO and Managing Partner	Goldman Sachs	<ul> <li>Formerly with Goldman, Sachs &amp; Co. in New York and San Francisco from 1995-2002</li> <li>Formerly Co-Head of Goldman Sachs' Financial Technology Group (#1 market share)</li> <li>Wharton M.B.A.</li> </ul>	21
Larry Furlong  Managing Director	Goldman Sachs	<ul> <li>Formerly with Goldman, Sachs &amp; Co. in New York, London and Los Angeles beginning in 1995</li> <li>Wharton M.B.A.</li> </ul>	21
Greg Smith  Managing Director	Merrill Lynch J.P.Morgan sterne agee	<ul> <li>Formerly award winning Equity Research Analyst at Merrill Lynch / J.P. Morgan / Sterne Agee</li> <li>Recent coverage included V, MA, TSS, GPN, HPY, DST, ENV, FISV, FIS &amp; JKHY among others</li> </ul>	20
Tim Wolfe  Managing Director	Goldman Sachs	<ul> <li>Formerly with Goldman, Sachs &amp; Co. beginning in 2000</li> <li>40 Under 40 M&amp;A Advisor Award Winner 2013</li> <li>Harvard M.B.A.</li> </ul>	14
Andrew McLaughlin  Managing Director, Research & Business Development	Deloitte.	<ul> <li>Leads FT Partners' Research and Business Development Team</li> <li>Formerly with Deloitte Consulting</li> </ul>	10



